James Loden is an Ophthalmology physician affiliated with Bausch Health. OpenAlex indexes 15 publications with 210 citations (h-index 4); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 Rivergate Parkway
Goodlettsville, TN 370722030
Telephone
615-859-3937Provider last certified this registry record 12 Nov 2025.
Clinical trials
- Laser Cataract Surgery With the Femtosecond Laser Technology
Sponsor: Innovative Medical
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- LENSAR, Inc.Program year20257 payments
- Glaukos CorporationProgram year20258 payments
- BIOTISSUE HOLDINGS INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
74.4%Prostaglandin Analog24.4%Latanoprost81%Lumigan19%Part D<11 patientsCarbonic Anhydrase Inhibitor16.9%Dorzolamide-Timolol54%Simbrinza46%Part D<11 patients+ 4 more classes in this area
Cardiovascular
10.3%Beta blocker10.3%Timolol Maleate100%Part D<11 patientsAnti-infectives
5.4%Fluoroquinolone Antibacterial5.4%Moxifloxacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and effectiveness comparison of a new cohesive ophthalmic viscosurgical device
Journal of Cataract & Refractive Surgery
2023 - Reply: Safety and effectiveness comparison of a new cohesive ophthalmic viscosurgical device
Journal of Cataract & Refractive Surgery
2023 - Clinical evaluation of a bacterially derived sodium hyaluronate 2.3% ophthalmic viscosurgical device
Journal of Cataract & Refractive Surgery
2019 - 5 features of successful comanagement
Optometry Times
2017
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”